Development of a nanosomal formulation of moxifloxacin based on poly(butyl-2-cyanoacrylate)

A nanosomal formulation of moxifloxacin has been prepared by anionic polymerization of poly(butyl-2-cyanoacrylate) in the presence of the drug. The poly(butyl-2-cyanoacrylate) nanoparticles absorb effectively moxifloxacin with a high total content and have a considerable capacity (> 45%). The influence of reaction parameters such as pH and drug-to-polymer ratio on the nanoparticle characteristics has been studied. The efficacy of the novel formulation has been evaluated in mice infected with M. tuberculosis . It is shown that the efficacy of the proposed nanosomal formulation for i.v. administration evaluated by a decrease in the lung mycobacteria count is more than twice that of a reference preparation.